AVTX
Avalo Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.63
+8.97%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-22.4%
Return on equity
-20.4%
Return on assets
-20.4%
Return on invested capital
0.00x
Asset turnover
-$66.4M
Cash from operations
$7.46
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026